{"url_path":"/sec/gild/8-k/2026-05-20/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Information.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/882095/0001104659-26-064518-index.html","accession_number":"0001104659-26-064518","cik":"0000882095","ticker":"GILD","issuer_name":"GILEAD SCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/882095/0001104659-26-064518-index.html","primary_entity_key":"0000882095","primary_entity_name":"GILEAD SCIENCES, INC."},"word_count":132,"has_tables":true,"body_markdown":"**Item 8.01.\nOther Information.**\n\n \n\nUnderwriting Agreement\n\n \n\nOn May 14, 2026, the Company\nentered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., BofA Securities, Inc. and\nCitigroup Global Markets Inc., as representatives of the several underwriters listed in Schedule 1 thereto, relating to the issuance and\nsale by the Company of the Notes.\n\n \n\n1\n\n \n\n \n\nThe description of the Underwriting\nAgreement contained herein is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 to this\nCurrent Report on Form 8-K and is incorporated herein by reference.\n\n \n\nThe above-mentioned offering\nwas made pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-273745). An opinion of counsel\nfor the Company is filed as Exhibit 5.1 to this Current Report on Form 8-K."}